Compare Eli Lilly And Co (LLY) vs Taskus Inc (TASK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Taskus Inc — how do they compare? Eli Lilly And Co trades at $1,173.02 (market cap $1.04T), while Taskus Inc trades at $8.18 (market cap $723.41M). The key difference: Eli Lilly And Co is far larger — about 1437.6× Taskus Inc's market cap, and Eli Lilly And Co pays a 0.59% dividend while Taskus Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Taskus Inc for 34 Days on average.
| LLY | TASK | |
|---|---|---|
Market Cap | $1.04T | $723.41M |
Volume | 3,064,878 | 201,303 |
Sector | Health | Technology |
52-Week High | $1.28K | $14.69 |
52-Week Low | $799.57 | $4.57 |
Typical Hold Time | 93 Days | 34 Days |
Enterprise Value | $1.09T | $1.09B |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
TaskUs trades at $8.08, up 2.41% today, with a bearish technical signal but strong fundamentals including a low P/E of 6.8 and robust ROE of 25.43%. Recent Q2 2026 earnings beat estimates with $0.33 EPS versus $0.29 expected, driven by 5% revenue growth to $308.9 million. The company shows consistent cash flow generation with $137 million from operations in 2025.
The stock appears undervalued with analyst consensus target of $9.33 offering 15% upside potential. Key risks include margin compression from higher labor costs and dependence on AI segment growth. Institutional ownership increased with Dimensional Fund Advisors raising its stake by 12.8% in Q1 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Taskus Inc
TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to innovative and disruptive technology companies. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.
Read more on TASK →
